Logo

Exelixis Entered into New License Agreement with Catalent for Three Antibody-Drug Conjugate Programs

Share this
Exelixis Entered into New License Agreement with Catalent for Three Antibody-Drug Conjugate Programs

Exelixis Entered into New License Agreement with Catalent for Three Antibody-Drug Conjugate Programs

Shots:

  • Catalent will receive $30M up front in exchange for rights to 3 biologics programs & is also eligible to receive development & sales milestones along with royalties. Exelixis gets an exclusive license to 3 target programs with lead Abs & ADC candidates
  • Exelixis will be responsible to fund the development work conducted by Catalent, following completion of the development candidate selection & lead to conducting preclinical, clinical & commercial activities
  • The agreement will expand Exelixis’ portfolio to include 3 targets in multiple solid tumor indications. Exelixis & Catalent signed a separate agreement in Sept 2020 where Catalent is using its SMARTag bioconjugation platform to create ADCs using mAbs from Exelixis' expanding preclinical pipeline

Ref: Businesswire | Image: Exelixis

Click here to­ read the full press release 

Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions